Please assess the completion status of the following clinical trial:

Trial Title: Hepcidine and Iron Deficiency in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hospitalized man/woman in reanimation unit for at least 5 days.~2. Age ≥ 18 years old.~3. Patient having an anaemia such as defined by the WHO (World Health Organization) (for man: Hemoglobin \< 13 g/dl, for woman: Hemoglobin \< 12 g/dl).~4. Signed inform consent by the patient or a close person.~5. Subject affiliated to a national health insurance~Exclusion Criteria:~1. Known iron metabolism pathology (such as primitive or secondary hemochromatosis, ...).~2. Chronic anaemia (Hemoglobin ≤ 10 g/dl for more than 3 months).~3. Current chemotherapy.~4. Patient having an organ transplant~5. Expected survival \< 28 days post Intensive Care Unit discharge.~6. Pregnancy~7. Patient deprived of freedom, by judicial or administrative order.~8. Major protected by the law.~9. Contra-indication to the injectable iron treatment (allergy to ferric carboxymaltose, infection derivates (bacteriamy \< 48 hours) untreated).~10. Non speaking French patient, or patient unable to answer a questionnaire because of any neurologic disorder (stroke, brain trauma....).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosage of hepcidin (Type: EXPERIMENTAL): In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
- Usual biomarker dosage (Type: ACTIVE_COMPARATOR): In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)

Based on this trial design, predict the completion outcome and termination type (if applicable).